IDEAYA Biosciences (IDYA) Announces $150M Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Ideaya (IDYA) PT Raised to $30 at Oppenheimer, 'we believe, at this market cap. near-term focus now shifts to the pipeline. Reiterate Outperform'
April 24, 2023 10:39 AM EDTOppenheimer analyst Matthew Biegler raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $30.00 (from $26.00) while maintaining a Outperform rating.
The analyst comments "Monday, IDEAYA held a call to discuss updates from its darovasertib franchise in uveal melanoma. With nearly twice... More
Stifel Upgrades Ideaya Biosciences (IDYA) to Buy 'on Increased Conviction in the Darovasertib 1L MUM Opportunity'
April 24, 2023 5:51 AM EDT(Updated - April 24, 2023 5:51 AM EDT)
Stifel analyst Ben Burnett upgraded Ideaya Biosciences (NASDAQ: IDYA) from Hold to Buy with a price target of $24.00 (from $18.00).
The analyst comments "We are upgrading shares to Buy following additional darovasertib data in Uveal Melanoma; which notably... More
IDEAYA Biosciences (IDYA) Reports Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting
April 24, 2023 5:29 AM EDTIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced further interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib combination in metastatic uveal melanoma (MUM) patients (ClinicalTrials.gov Identifier: NCT03947385).
"The observed efficacy in first-line metastatic uveal melanoma patients including confirmed ORR of 45% and median PFS of ~ 7 months is clinically significant and represents a potential paradigm shift for treating MUM patients. The... More
